Kidney Cancer Coverage from Every Angle

Proteogenomics May Improve Diagnosis and Treatment of Kidney Cancer Subtype

By: Cordi Craig
Posted: Tuesday, November 19, 2019

Investigators of a new study suggest that integrating genomic, epigenomic, transcriptomic, proteomic, and phosphoproteomic measurements for tumors appears to help develop a deeper understanding of clear cell renal cell carcinoma. The study, published in Cell, reported evidence for at least four distinct subtypes of clear cell renal cell carcinoma and new information on the proteins associated with the disease. David J. Clark, PhD, of Johns Hopkins University, Baltimore, and colleagues suggest these findings may help inform overall patient survival and therapeutic interventions.

To determine the proteogenomic characteristics of clear cell renal cell tumors, the researchers analyzed tumor samples from 110 treatment-naive patients and paired 84 healthy tissue samples surrounding the tumors. The loss of chromosome 3p occurred in almost all of the tumor samples in the study and may be a revealing sign of clear cell renal cell carcinoma. The researchers also identified four distinct immune-based subtypes of clear cell renal cell carcinoma based on cellular pathways using microenvironment cell signatures. The four subtypes included CD8-positive inflamed tumors, CD8-negative inflamed tumors, vascular endothelial growth factors immune desert tumors, and metabolic immune desert tumors. These findings provide evidence that tumor pathobiology may help with rational treatment selection for patients with clear cell renal cell carcinoma and, as a result, may reveal biologic insights on tumor characteristics and the complexity of cancer development that would otherwise remain unknown.

“The use of one type of molecular study to understand cancer is no longer enough. A multiomic approach is needed to fully characterize cancer,” Dr. Clark concluded in a Johns Hopkins press release. Next up for the team is to use similar methods to more fully characterize pancreatic and head/neck cancers.

Disclosure: For full disclosures of study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.